127 related articles for article (PubMed ID: 36135951)
1. Tacrolimus therapy in primary Sjögren's syndrome with refractory immune thrombocytopenia: a retrospective study.
Xu R; Yan Q; Gong Y; Cai CS; Wu J; Yuan XY; Long XM
Clin Exp Rheumatol; 2022 Dec; 40(12):2268-2274. PubMed ID: 36135951
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of bone marrow megakaryocyte count for immunotherapeutic response in primary Sjögren's syndrome patients with severe immune thrombocytopenia: A single-center case-control study in China.
Zhong H; Xue Y; Zhang L; Yang Y; Zhou J; Zhang S; Jiang N; Qiao L; Peng L; Wang L; Zhang W; Xu D; Li M; Zhao Y; Zeng X
Int J Rheum Dis; 2023 Jul; 26(7):1260-1267. PubMed ID: 37183556
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and treatment responses of immune thrombocytopenia in patients with primary Sjögren syndrome.
Sun F; Tang Q; Cheng W; Xie X; Li F; Chen J
Int Immunopharmacol; 2023 Oct; 123():110716. PubMed ID: 37506503
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and mechanism for action of iguratimod in primary Sjögren's syndrome patients.
Jiang W; Zhang L; Zhao Y; He X; Hu C; Liu Y
Int Ophthalmol; 2020 Nov; 40(11):3059-3065. PubMed ID: 32607949
[TBL] [Abstract][Full Text] [Related]
6. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
7. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
8. Primary Sjogren's syndrome and autoimmune cytopenias: a relation often overlooked.
Khattri S; Barland P
Bull NYU Hosp Jt Dis; 2012; 70(2):130-2. PubMed ID: 22892005
[TBL] [Abstract][Full Text] [Related]
9. Iguratimod treatment reduces disease activity in early primary Sjögren's syndrome: An open-label pilot study.
Chen H; Qi X; Li Y; Wu Q; Shi Q; Wang L; Li J; Zhao L; Zhang L; Zhou X; Fei Y; Liu J; Su J; Wu D; Yang Y; Jiang H; Zeng X; Zhang F; Zhao Y
Mod Rheumatol; 2021 Mar; 31(2):394-398. PubMed ID: 32613869
[TBL] [Abstract][Full Text] [Related]
10. Abatacept treatment of patients with primary Sjögren's syndrome results in a decrease of germinal centres in salivary gland tissue.
Haacke EA; van der Vegt B; Meiners PM; Vissink A; Spijkervet FK; Bootsma H; Kroese FG
Clin Exp Rheumatol; 2017; 35(2):317-320. PubMed ID: 27908305
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
Shao Q; Wang S; Jiang H; Liu L
Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
[No Abstract] [Full Text] [Related]
12. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.
Kedor C; Zernicke J; Hagemann A; Gamboa LM; Callhoff J; Burmester GR; Feist E
Clin Rheumatol; 2016 Sep; 35(9):2203-10. PubMed ID: 27470087
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with secondary immune thrombocytopenia in patients with primary Sjögren's syndrome: a retrospective study of 639 cases.
Luo J; Song WJ; Chen JQ; Yang GY; Yang JY; Yu XB; Huang ZW; Xu Y; Wang JM; Tao QW
Clin Exp Rheumatol; 2022 Dec; 40(12):2245-2252. PubMed ID: 35383565
[TBL] [Abstract][Full Text] [Related]
14. [Cyclic thrombocytopenia complicated with Sjögren syndrome and the mechanism of periodic platelet count fluctuation].
Yamauchi N; Muramatsu H; Inomata H; Numata T; Nozawa E; Nishino M; Koyama R; Ihara K; Nishisato T; Hirayama M; Katsuki S; Matsunaga T; Niitsu Y
Rinsho Ketsueki; 2008 Aug; 49(8):658-63. PubMed ID: 18800616
[TBL] [Abstract][Full Text] [Related]
15. High-dose methylprednisolone pulse therapy upregulated FcγRIIb expression on B cells in primary Sjögren's syndrome patients with thrombocytopenia.
Chen H; Zhou S; Su D; Lu L; Li X; Sun L
Clin Rheumatol; 2013 Dec; 32(12):1783-90. PubMed ID: 23917390
[TBL] [Abstract][Full Text] [Related]
16. Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.
Delli K; Haacke EA; Kroese FG; Pollard RP; Ihrler S; van der Vegt B; Vissink A; Bootsma H; Spijkervet FK
Ann Rheum Dis; 2016 Nov; 75(11):1933-1938. PubMed ID: 26757748
[TBL] [Abstract][Full Text] [Related]
17. [The efficacy and safety of low-dose rituximab in treatment of primary Sjögren's syndrome with thrombocytopenia].
Zhou L; Xin XF; Wu HX
Zhonghua Nei Ke Za Zhi; 2012 Jan; 51(1):37-41. PubMed ID: 22490758
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus for the treatment of patients with refractory connective tissue disease-related thrombocytopenia: a pilot study.
Du H; Su W; Su J; Hu J; Wu D; Long W; Zhu J
Rheumatology (Oxford); 2024 Jan; 63(1):79-84. PubMed ID: 37079730
[TBL] [Abstract][Full Text] [Related]
19. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
Akiyama M; Sasaki T; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):157-164. PubMed ID: 29465360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
